Introduction

Molecular Medicine Reports

1791-2997 1791-3004

D.A. Spandidos

10.3892/mmr.2025.13648

MMR-32-4-13648

Articles

Anti-inflammatory and anti-migratory properties of wild-grape-derived ε-viniferin in human endometrial cells: A potential therapy for endometriosis

Lin

Yinzhi

1 2 Naiki

Yoshikazu

3 Kojima

Shiori

1 4 Hakamata

Masatoshi

1 5 Fukatsu

Hitomi

4 Hasegawa

Yoshiaki

3 Wakatsuki

Akihiko

6 Koide

Naoki

2 Umezawa

Kazuo

1Department of Molecular Target Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan 2Department of Microbiology and Immunology, Aichi Medical University, Nagakute, Aichi 480-1195, Japan 3Department of Microbiology, School of Dentistry, Aichi Gakuin University, Nagoya, Aichi 464-8650, Japan 4Fukuyu Medical Institute, Fukuyu Medical Corporation, Nisshin, Aichi 470-0103, Japan 5Biotechnology Section, Industrial Research Institute of Shizuoka Prefecture, Numazu, Shizuoka 410-0022, Japan 6Department of Obstetrics and Gynecology, Aichi Medical University, Nagakute, Aichi 480-1195, Japan

Correspondence to: Dr Yoshikazu Naiki, Department of Microbiology, School of Dentistry, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa, Nagoya, Aichi 464-8650, Japan, E-mail: naikiy@dpc.agu.ac.jp

102025

07082025

32 4

283

14032025 27062025

2025

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Endometriosis is a chronic gynecological disorder characterized by the ectopic growth and proliferation of endometrial tissue outside the uterine cavity, leading to inflammation. Although low-dose contraceptive pills are widely used for its treatment, these therapies are associated with side effects and are contraindicated in women trying to conceive. ε-viniferin is a resveratrol dimer found in wild grapes (Ampelopsis brevipedunculata) with demonstrated antioxidant properties and an anti-migratory effect in lung cancer cells. Because abnormal cell migration is a key process in endometriosis, we hypothesized that ε-viniferin could also exhibit anti-migratory effects in endometriotic cells, which remain to be elucidated. To test this hypothesis, the present study investigated the anti-inflammatory and anti-endometriotic effects of ε-viniferin and wild-grape extract. RAW264.7 and THP-1 were used to evaluate the anti-inflammatory effects of wild-grape extract and ε-viniferin by assessing cytotoxicity; nitric oxide (NO), reactive oxygen species and interleukin-6 (IL-6) production; and NF-κB activity. Additionally, human endometrial stromal cells (HESCs) were used to investigate the anti-endometriotic effects of ε-viniferin, including its impact on cell migration, invasion and gene expression, using PCR array analysis. Both ε-viniferin and wild-grape extract significantly reduced lipopolysaccharide-induced NO and IL-6 production, indicating an anti-inflammatory activity. Inhibition of NF-κB activity at the cellular level further supported these findings. Moreover, both ε-viniferin and wild-grape extract effectively suppressed the migration and invasion of HESCs, indicating their potential to alleviate endometriosis symptoms. These findings suggest that ε-viniferin is a promising therapeutic candidate for endometriosis, exhibiting both anti-inflammatory and anti-migratory effects. Our results present a novel approach for developing effective anti-endometriotic therapies.

ε-viniferin wild-grape exact endometriosis inflammation migration invasion

Japan Society for the Promotion of Science Kakenhi

22H03062

Japan Agency for Medical Research and Development

JP18fk0310118JSPS

Fukuyu Medical Corporation

This work was supported by the Japan Society for the Promotion of Science Kakenhi (grant no. 22H03062) and the Japan Agency for Medical Research and Development (grant no. JP18fk0310118JSPS). Additional financial support was provided by Fukuyu Medical Corporation.

Introduction

Endometriosis is a prevalent gynecological disorder associated with female infertility. It affects approximately 10% of women of reproductive age and 25–50% of women experiencing infertility. This disorder is characterized by the growth of endometrial tissue outside the uterine cavity, leading to symptoms such as inflammation, dysmenorrhea, infertility, and dyspareunia. These symptoms significantly impair the quality of life for women and are often accompanied by psychological burdens (1,2).

However, effective long-term management of endometriosis remains challenging despite the availability of treatment options that include both surgical and non-surgical approaches. Surgical approaches for endometriosis include minimally invasive techniques such as laparoscopy, laser ablation, and electrocoagulation for early-stage cases, whereas advanced surgical procedures such as laparotomy, oophorectomy, and colorectal surgery are required for deep infiltrating endometriosis. However, these interventions carry risks, including recurrence due to incomplete excision, ovarian dysfunction, voiding impairment, and tissue damage (3–5). Several non-surgical treatment options are currently available for managing endometriosis, with the most common approaches being hormone therapy and pain management. Low-dose oral contraceptives, which contain estrogen and progesterone, are widely used and are shown to alleviate menstrual pain, ameliorate infertility, reduce dyspareunia, and shrink endometriotic lesions. However, these treatments are associated with adverse effects, such as nausea, headache, and breakthrough bleeding, and an increased risk of thrombosis with long-term use. Additionally, they are contraindicated in women who wish to conceive (3–6). Other treatment options include aromatase inhibitors and progestin-based medications. Aromatase inhibitors are drugs that inhibit the enzyme aromatase, which converts androgens, the precursors of estrogen, into estrogen, thereby suppressing estrogen production. Although aromatase inhibitors reduce dysmenorrhea and shrink lesions, they are expensive and decrease bone mineral density (7,8). Progestin-based medications, which suppress estrogen activity and inhibit endometrial proliferation, also cause adverse effects such as breakthrough bleeding, and their efficacy is typically lower than that of low-dose oral contraceptives (9). Other treatment options, such as nonsteroidal anti-inflammatory drugs (such as ibuprofen), carry cardiovascular risks with long-term use, whereas neuromodulators and antidepressants (such as gabapentinoids) used for chronic pain management may lead to dependency (10,11). Hence, effective and safe treatment options must be explored for endometriosis.

Recently, considerable progress has been made in understanding the pathophysiology of endometriosis; genetic and immunological factors involved in the ectopic occurrence, proliferation, and invasion of endometrial tissue are gradually being elucidated. For instance, interleukin (IL)-8 and endothelin, secreted by ectopic endometrial tissue, promote inflammatory responses mediated by immune cells and contribute to symptoms such as pain and complications such as adhesions (12–14). These advances in understanding have spurred efforts to develop alternative treatment methods. Subsequently, natural compounds are being researched as effective therapeutic options with minimal side effects for endometriosis, and the potential of resveratrol, an anti-inflammatory and antioxidant compound, for the treatment of endometriosis has been demonstrated (15–17). However, the therapeutic utility of resveratrol is limited by its low absorption rates. In contrast, ε-viniferin, a dimer of resveratrol, exhibits increased lipophilicity, which enhances membrane permeability and absorption in the gastrointestinal tract and liver (Fig. 1). Pharmacokinetic studies have also demonstrated high bioaccumulation of ε-viniferin in white adipose tissue, suggesting that these tissues may serve as a reservoir for its native form, enabling slow release and prolonged systemic presence (18–20).

ε-viniferin is the main functional compound in wild grapes (Ampelopsis brevipedunculata), with antioxidant, anti-inflammatory, and anti-tumor effects (21–24). It also has neuroprotective effects, which may be beneficial in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases (25), and preventive effects against obesity-related morbidities, such as type 2 diabetes, dyslipidemia, hypertension, and fatty liver (26). ε-viniferin inhibits TGF-β1-induced epithelial-mesenchymal transition, migration, and invasion in lung cancer cells by downregulating vimentin (27). Elevated levels of TGF-β1 have also been implicated in the development of endometriosis by promoting cell migration and invasiveness (28). Given these shared mechanistic pathways, we hypothesized that ε-viniferin exerts beneficial effects in endometriosis by inhibiting key processes involved in the disease. However, its potential effects on endometrial cells remain unclear.

In this study, we aimed to investigate the anti-inflammatory effects of ε-viniferin and wild-grape extract, along with their inhibitory effects on the migration and invasion of human endometrial stromal cells (HESCs). We believe that our findings would contribute to the development of ε-viniferin as a potential therapeutic option for the effective management of endometriosis.

Materials and methods <sec> <title>Materials

Wild-grape extract (cat. no. 30811033) and ε-viniferin (cat. no. NS3013) were purchased from Maruzen Pharmaceuticals Co., Ltd. and Nagara Science Co., Ltd., respectively.

Cell culture

Mouse macrophage-like cell line RAW264.7 (RRID:CVCL_0493, cat. no. TIB-71; American Type Culture Collection) and human monocytic leukemia cell line THP-1 (RRID:CVCL_0006, cat. no. RCB3686; Riken Bioresource Center) were cultured in RPMI1640 medium (cat. no. 189-02025; FUJIFILM Wako Pure Chemical Corporation) supplemented with 10% inactivated fetal bovine serum (cat. no. F7524, non-USA origin; Sigma-Aldrich; Merck KGaA) and 1% (v/v) penicillin-streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a humidified incubator with 5% CO₂. THP-1 cells (1.5×10⁴ cells/well) were seeded into 96-well plates and differentiated into macrophage-like cells using 0.1 µg/ml phorbol 12-myristate 13-acetate (PMA; cat. no. P1585; Sigma-Aldrich; Merck KGaA) for 72 h.

To investigate the potential application of ε-viniferin for its anti-endometriotic effects, we used HESCs, which are derived from ectopic endometrial tissues associated with endometriosis and drive the abnormal migration and invasion of endometrial tissue.

Immortalized HESCs (cat. no. T0533; Applied Biological Materials Inc., Richmond, BC, Canada, http://www.abmgood.com/immortalized-human-endometrial-stromal-cells-hesc.html) were cultured in Prigrow IV medium (cat. no. TM004; Applied Biological Materials, Inc.) supplemented with 2 mM L-Glutamine (cat. no. G275; Applied Biological Materials, Inc.), 10% charcoal-stripped fetal bovine serum (cat. no. 12676-029; Gibco), and 1% (v/v) penicillin-streptomycin at 37°C in a humidified incubator containing 5% CO₂.

Cell viability

RAW264.7 cells (3×10⁴ cells/well) were seeded into 96-well plates and incubated for 1 h. Differentiated THP-1 cells were rinsed with phosphate-buffered saline (PBS) and fresh medium before overnight incubation. HESCs (1.5×10⁴ cells/well) were seeded into 96-well plates and incubated overnight. The test chemicals, namely, wild-grape extract at 0.03, 0.1, and 0.3 mg/ml and ε-viniferin at 3, 10, and 30 µg/ml, were added, and the cells were incubated for an additional 24 h at 37°C. Dimethyl sulfoxide (DMSO) was used as the control. MTT reagent (working concentration: 0.5 mg/ml; cat. no. 10009591; Cayman Chemical) was added to each well and incubated for 2 h at 37°C. The supernatant was replaced with 100 µl of DMSO to dissolve the formazan crystals. Absorbance was measured at 570 nm using a microplate reader (Bio-Rad Laboratories).

Nitric oxide (NO) production

RAW264.7 cells (3×10⁴ cells/well) were seeded into 96-well plates and incubated for 1 h. Test chemicals were added to each well and incubated for an additional hour, followed by exposure to lipopolysaccharide (LPS, 100 ng/ml; cat. no. L5293; Sigma-Aldrich; Merck KGaA) for 24 h. The supernatant was collected, and 50 µl aliquots were mixed with an equal volume of Griess reagent in a 96-well plate. Absorbance was measured at 570 nm using a microplate reader (Bio-Rad Laboratories).

Measurement of IL-6 production RAW264.7 cells (3×10<sup>4</sup> cells/well) were seeded into 96-well plates and incubated for 1 h

Differentiated THP-1 cells were washed with PBS and fresh medium before overnight incubation. The test chemicals, namely, wild-grape extract at 0.1, 0.2, and 0.3 mg/ml and ε-viniferin at 10, 20, and 30 µg/ml, were added to each well and incubated for 1 h, followed by exposure to LPS (100 ng/ml) for 24 h. IL-6 concentration in the supernatants were measured using Mouse IL-6 ELISA Kit (cat. no. M6000B; R&D Systems) for RAW264.7 cells and Human IL-6 ELISA Kit (cat. no. D6050; R&D Systems) for THP-1 cells, following the manufacturer's protocol. Plates were washed four times, and horseradish peroxidase-conjugated IL-6 was added, followed by a 2 h incubation at 23–25°C. Substrate solutions of tetramethylbenzidine (TMB) and hydrogen peroxide were added to each well after washing four times, and plates were incubated for 20 min at room temperature in the dark. The reaction was quenched using diluted hydrochloric acid. Absorbance was measured at 450 nm using a microplate reader (Bio-Rad Laboratories).

Measurement of reactive oxygen species (ROS) production

RAW264.7 cells (3×10⁴ cells/well) were seeded into 96-well plates and incubated overnight. Test chemicals at various concentrations were added, and the cells were incubated for 1 h, followed by exposure to LPS (100 ng/ml) for 24 h at 37°C. ROS production was determined using DCFH-DA (20 µM; cat. no. 35845; Sigma-Aldrich; Merck KGaA), an oxidant-sensitive fluorescent probe. The medium was removed from each well, and the cells were washed twice with Ca²⁺, Mg²⁺-free PBS (PBS-) and incubated with DCFH-DA for 30 min. After removing the supernatant and washing twice with PBS-, 200 µl PBS- was added to each well. Fluorescence was measured with excitation and emission wavelengths of 485 nm and 535 nm, respectively, using a fluorescence plate reader (SpectraMax M5; Molecular Devices).

Measurement of DPPH radical scavenging ratio

The scavenging effect was assessed using the DPPH Antioxidant Assay Kit (cat. no. D678; Dojindo). Briefly, 20 µl of the sample solution was added to each well of a 96-well microplate, followed by 80 µl of assay buffer and 100 µl of 2,2-diphenyl-1-picrylhydrazyl (DPPH) working solution. Wild-grape extract solutions (at 0.1, 0.3, and 1 mg/ml) and ε-viniferin (at 3, 10, and 30 µg/ml) were used as samples. Trolox at 80 µg/ml was used as a positive control. The plate was incubated for 30 min at room temperature in the dark. Absorbance was measured at 517 nm using a microplate reader (SpectraMax M5).

RNA isolation, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and reverse transcription-PCR (RT-PCR)

RAW264.7 cells (1×10⁶ cells/well) were seeded into 60 mm dishes and incubated for 24 h. Test chemicals were added to each dish and incubated for 1 h, followed by LPS treatment (100 ng/ml) for 4 h at 37°C. RNA was extracted using TRIzol reagent (1 ml; cat. no. 15596018; Invitrogen; Thermo Fisher Scientific, Inc.) and reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (cat. no. 4368814; Applied Biosystems; Thermo Fisher Scientific, Inc., Vilnius, Lithuania) at 25°C for 10 min, 37°C for 120 min, and 85°C for 5 min. For RT-qPCR, cDNA was amplified in triplicate using KOD FX Neo PCR Buffer (14 µl) and dNTPs (cat. no. KFX-201; Toyobo Co., Ltd.). Target DNA sequences for each primer pair were amplified in triplicate under the following conditions: initial denaturation at 94°C for 10 sec, followed by 40 cycles of 94°C for 10 sec, 60°C for 10 sec, and 70°C for 20 sec, using the QuantStudio 3 system (Applied Biosystems, Singapore). mGapdh and ACTB were used as internal controls. Relative mRNA expression levels were calculated using the 2^−ΔΔCq method (29).

For RT-PCR, PCR products were separated on a 2% agarose gel, and the band intensities were analyzed using ImageJ software (ImageJ 1.53e with Java 1.8.0_172; National Institutes of Health). The following primer pairs were used: mouse iNOS, 5′- GTCTTGCAAGCTGATGGTCA-3′ (forward) and 5′-ACCACTCGTACTTGGGATGC-3′ (reverse); mouse Il1β, 5′-CGTGGACCTTCCAGGATGAG-3′ (forward) and 5′-GGAGCCTGTAGTGCAGTTGTC-3′ (reverse); mouse Il6, 5′-ACCACGGCCTTCCCTACTTC-3′ (forward) and 5′-CACAACTCTTTTCTCATTTCCACG-3′ (reverse); human IL6, 5′-AGACAGCCACTCACCTCTTCAG-3′ (forward) and 5′- TTCTGCCAGTGCCTCTTTGCTG-3′ (reverse); mouse Gapdh, 5′-TGCACCACCAACTGCTTAG-3′ (forward) and 5′-GATGCAGGGATGATGTTC-3′ (reverse); and human ACTB, 5′-CTTCTACAATGAGCTGCGTG-3′ (forward) and 5′-TCATGAGGTAGTCAGTCAGG-3′ (reverse).

Wound healing assay

HESCs (1×10⁵ cells/well) were seeded into 24-well plates and cultured overnight until confluence. A uniform scratch was created across the center of the well using a 200 µl pipette tip. Floating cells and the growth medium were removed, and serum-free medium containing the test chemicals was added to each well. Cells were incubated for an additional 8 h, and their movement into the scratched area was recorded every 2 h using a phase-contrast microscope (Nikon Eclipse TS100).

Matrigel invasion chamber assay

HESCs (5×10⁴ cells/well) suspended in 500 µl serum-free Prigrow IV medium containing test chemicals were seeded into commercial Matrigel-coated chambers (BD Matrigel Basement Membrane Matrix; cat. no. 354480; Corning). The lower chambers were filled with 750 µl of Prigrow IV medium with 10% FBS and were incubated for 16 h at 37°C. Thereafter, non-invading cells were removed by wiping the upper surface of the membrane with a cotton swab, and invading cells on the lower surface of the membrane were stained with Diff-Quick (cat. no. 16920; Sysmex) according to the manufacturer's instruction and counted under a phase-contrast microscope (Nikon Eclipse TS100).

PCR array

Total RNA was extracted from HESCs using the RNeasy Mini Kit (cat. no. 74106; Qiagen, Hilden, North Rhine-Westphalia, Germany), treated with ε-viniferin for 8 h, and reverse transcribed using the RT² First Strand Kit (cat. no. 330401; Qiagen, Germantown, MD, USA). The cDNA was applied to the Human Tumor Metastasis PCR Array (cat. no. 330231; Qiagen, Germantown, MD, USA) using RT² SYBR-Green ROX qPCR Mastermix (cat. no. 330520; Qiagen, Germantown, MD, USA). Data were analyzed using the 2^−ΔΔCq method (29).

Measurement of NF-κB activity

RAW264.7 cells (3×10⁶ cells/well) were seeded into 6-well plates and incubated for 1 h. Test chemicals at various concentrations were added to each well and incubated for 1 h, followed by LPS treatment (100 ng/ml) for 2 h at 37°C. Nuclear extracts were prepared using the Nuclear Extract Kit (cat. no. 40010; Active Motif) according to the manufacturer's instructions. NF-κB binding activity was measured using nuclear extract (5 µg) with the TransAM NF-κB p65 Transcription Factor Assay Kit (cat. no. 40096; Active Motif).

Statistical analysis

Results are presented as mean±standard deviation (SD). Statistical analysis was performed using GraphPad Prism version 10.0 (Dotmatics). Differences between the two groups were analyzed using the Student's t-test. One-way analysis of variance (ANOVA) followed by Dunnett's post-hoc test was used for comparisons among more than two groups. Statistical significance was set at P<0.05.

Results <sec> <title>Wild-grape extract suppresses inflammatory regulators and ROS in RAW264.7 cells

The anti-inflammatory effects of wild-grape extract were evaluated in RAW264.7 cells. Wild-grape extract was not cytotoxic to RAW264.7 cells after 24 h of treatment at concentrations below 0.3 mg/ml (Fig. 2A). The extract suppressed LPS-induced NO and ROS production in RAW264.7 cells (Fig. 2B and C) and exhibited significant dose-dependent antioxidant activity in the DPPH assay (Fig. 2D). As inducible nitric oxide synthase (iNOS) is responsible for NO production, we explored the effect of wild-grape extract on LPS-induced iNOS and the expression of downstream inflammatory factors, IL-6 and IL-1β. Although wild-grape extract did not inhibit LPS-induced iNOS or IL-1β expression, it significantly inhibited LPS-induced IL-6 expression (Fig. 2E). We further validated this inhibition using RT-qPCR and ELISA in RAW264.7 cells (Fig. 2F and G). These findings indicate that wild-grape extract suppresses ROS-activated IL-6 inflammatory reactions in RAW264.7 cells.

ε-viniferin reduces inflammation through ROS suppression and NF-κB inhibition in RAW264.7 cells

We investigated the anti-inflammatory action of ε-viniferin in RAW264.7 cells. ε-viniferin was not cytotoxic to RAW264.7 cells after 24 h of treatment at concentrations below 10 µg/ml (Fig. 3A). ε-viniferin, similar to wild-grape extracts, showed significant dose-dependent antioxidant activity in the DPPH assay (Fig. 3B). Although ε-viniferin did not suppress LPS-induced NO production (Fig. 3C), it suppressed LPS-induced ROS production at non-toxic concentrations (Fig. 3D). These results suggest that the anti-inflammatory effects of ε-viniferin partially stem from the suppression of ROS production.

We then explored the effects of ε-viniferin on IL-6 production in RAW264.7 cells because wild-grape extract inhibited LPS-induced IL-6 production and IL-6 production is an early response in LPS-induced inflammatory reaction. Within 4 h of exposure, ε-viniferin was not cytotoxic to RAW264.7 cells at a concentration of 30 µg/ml (Fig. 3E). However, it significantly inhibited LPS-induced IL-6 production both at gene and protein levels (Fig 3F and G).

We also tested the effect of ε-viniferin on NF-κB activity, as this transcription factor is present upstream of IL-6, and NF-κB activation was significantly suppressed by ε-viniferin in a concentration-dependent manner (Fig. 3H). These results suggest that the NF-κB-mediated IL-6 signaling pathway is central to the anti-inflammatory effects of ε-viniferin in RAW264.7 cells.

ε-viniferin exhibits anti-inflammatory effects in human macrophage-like THP-1 cells

To further validate the anti-inflammatory effects of ε-viniferin, we used THP-1 cells, which differentiate into macrophage-like cells upon stimulation with phorbol esters such as phorbol-12-myristate-13-acetate (PMA). ε-viniferin (30 µg/ml) was not cytotoxic to THP-1 cells after 4 h of treatment (Fig. 4A). ε-viniferin significantly suppressed LPS-induced IL6 mRNA expression at 20 µg/ml and its protein production at 10 µg/ml (Fig. 4B and C). These results confirm that ε-viniferin exhibits anti-inflammatory effects in both mouse- and human-derived macrophage-like cells.

ε-viniferin inhibits migration and invasion of HESCs and modulates inflammatory signaling pathways

ε-viniferin was not cytotoxic to HESCs at concentrations below 10 µg/ml (Fig. 5A). It suppressed HESC migration at a concentration of 1 µg/ml and invasion at concentrations of 3 µg/ml and above (Fig. 5B and C). Similar inhibitory effects on migration and invasion were observed with wild-grape extract (Fig. S1A-C).

To further investigate the inflammatory signaling pathways potentially involved in the anti-endometriotic effects of ε-viniferin, a PCR array was employed (Fig. S2). Treatment of HESCs with ε-viniferin upregulated CDKN2A, a gene that inhibits abnormal cell growth and proliferation, and downregulated TNFSF10, a regulator of inflammation. Additionally, ε-viniferin suppressed the expression of metastasis-promoting genes such as HPSE and FGFR4.

Discussion

In this study, we investigated the anti-inflammatory and anti-endometriotic effects of wild-grape extract and purified ε-viniferin and demonstrated that both compounds effectively suppressed LPS-induced inflammatory mediators, including NO, ROS, and IL-6, in mouse and human macrophage cell lines. They also inhibited the activation of NF-κB, a transcription factor that regulates the expression of these mediators. These findings suggest that wild-grape extract and purified ε-viniferin exhibit anti-inflammatory activity by inhibiting NF-κB mediated inflammatory pathways. Furthermore, we validated the previously demonstrated radical scavenging activity of ε-viniferin in vitro. ε-viniferin consists of two stilbenol units linked together, and its radical-scavenging activity is attributed to the functional groups such as phenolic hydroxyl groups and double bonds within this structure (30,31).

Previously, we reported the potential of NF-κB inhibitor dehydroxymethylepoxyquinimicin (DHMEQ) in the treatment of endometriosis (32). Based on these findings and the observed NF-κB inhibition by ε-viniferin, we further explored the potential application of ε-viniferin for its anti-endometriotic effects. We demonstrated that ε-viniferin effectively inhibited the migration and invasion of HESCs, a key cell type implicated in endometriosis. Thus, ε-viniferin exhibited potential for the treatment of endometriosis. Additionally, PCR array analysis revealed that ε-viniferin suppressed the expression of mobility-related genes, such as HPSE and FGFR4, and the inflammation-promoting mediator TNFSF10. The observed gene expression patterns revealed that ε-viniferin could inhibit the progression of endometriosis by modulating inflammatory regulators and metastasis-related pathways. To gain deeper mechanistic insights into ε-viniferin's molecular targets, future transcriptomic and/or proteomic analyses of HPSE and FGFR4 functions are warranted. In the present study, we focused on HESCs to assess the direct anti-migratory and anti-inflammatory effects of ε-viniferin. To further evaluate its therapeutic relevance in the endometriotic microenvironment, future studies will examine ε-viniferin's effects on other cellular components of endometriotic lesions, including epithelial cells, immune cells, and vascular endothelial cells.

While our current study focused on the NF-κB pathway, it is important to explore broader signaling networks to fully understand the therapeutic effects of ε-viniferin. Previous studies (22,27) reported that ε-viniferin suppresses inflammatory cytokines such as TNF-α and TGF-β, which are associated with the JAK/STAT and TGF-β pathways. These findings suggest that ε-viniferin may have broader anti-inflammatory effects beyond NF-κB inhibition. In addition, our PCR array data showed that ε-viniferin downregulated TNFSF10 (Fig. S2), a gene regulated by TRAIL and involved in immune and apoptotic pathways. These results support the potential of wider regulatory effects. Future studies will investigate the JAK/STAT and TGF-β pathways to further clarify ε-viniferin's therapeutic mechanisms.

Overall, our results suggest that ε-viniferin is a promising anti-endometriosis agent with potent anti-inflammatory effects, which are crucial for managing disease progression. ε-viniferin-based therapy may be a safer, non-hormonal alternative to conventional hormonal therapies, which often cause side effects such as bone loss and menstrual irregularities. While these findings strongly support the therapeutic potential of ε-viniferin, further in vivo and clinical studies are necessary to confirm its efficacy and long-term safety. Moreover, previous pharmacokinetic studies have shown that ε-viniferin accumulates in white adipose tissue and remains in the body for extended periods (18–20). However, critical pharmacokinetic parameters-such as absorption rate, metabolism, and plasma half-life-remain uncharacterized in the context of endometriosis. Pharmacokinetic modeling and in vivo biodistribution studies are therefore planned to optimize its therapeutic use. As a non-hormonal agent, ε-viniferin may also be considered for combination therapy. Although its interaction with standard hormonal treatments remains unexplored, previous studies have shown that resveratrol, a structurally related polyphenol, enhances the efficacy of hormonal therapies and improves the management of endometriosis-related pain by reducing inflammation (33). These findings raise the possibility that ε-viniferin may offer similar combinatorial benefits. To enhance clinical applicability, we also plan to explore combination therapies using ε-viniferin alongside standard hormonal treatments. Together, our findings present a novel strategy for developing anti-endometriosis therapies by targeting both inflammation and cell migration, paving the way for future translational research.

Supplementary Material

Supporting Data

Acknowledgements

The authors would like to thank Mr. Kazuyuki Ino (General Affairs Department, Fukuyu Hospital, Fukuyu Medical Corporation, Fukuyu, Japan) for providing support in writing and editing the manuscript.

Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

Authors' contributions

YL, KU, SK and YN contributed to the experimental design and manuscript preparation. YL, SK, MH and HF conducted the experiments. YH, AW and NK contributed to the experimental design. YL, YN and SK confirmed the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The Department of Molecular Target Medicine, to which KU belongs, is a funding-supported laboratory financially supported by Fukuyu Medical Corporation (Nisshin, Japan); Brunaise Co., Ltd. (Nagoya, Japan); Shenzhen Wanhe Pharmaceutical Company (Shenzhen, China); and Meiji Seika Pharma (Tokyo, Japan). This study is partly supported by Fukuyu Medical Corporation.

Abbreviations

THP-1

human monocytic leukemia cell line

HESCs

human endometrial stromal cells

References 1

Zondervan

Becker

Missmer

Endometriosis

N Engl J Med382124412562020

10.1056/NEJMra1810764

32212520

Pessoa de Farias Rodrigues

Lima Vilarino

de Souza Barbeiro Munhoz

da Silva Paiva

de Alcantara Sousa

Zaia

Parente Barbosa

Clinical aspects and the quality of life among women with endometriosis and infertility: A cross-sectional study

BMC Womens Health201242020

10.1186/s12905-020-00987-7

32532273

Johnson

Hummelshoj

World Endometriosis Society Montpellier Consortium

Consensus on current management of endometriosis

Hum Reprod28155215682013

10.1093/humrep/det347

23528916

Taylor

Kotlyar

Flores

Endometriosis is a chronic systemic disease: Clinical challenges and novel innovations

Lancet3978398522021

10.1016/S0140-6736(21)00389-5

33640070

Hee

Kettner

Vejtorp

Continuous use of oral contraceptives: An overview of effects and side-effects

Acta Obstet Gynecol Scand921251362013

10.1111/aogs.12036

23083413

De Corte

Milhoranca

Mechsner

Oberg

Kurth

Heinemann

Unravelling the causal relationship between endometriosis and the risk for developing venous thromboembolism: A pooled analysis

Thromb Haemost1253853942025

10.1055/a-2407-9498

39222924

Polyzos

Fatemi

Zavos

Grimbizis

Kyrou

Velasco

Devroey

Tarlatzis

Papanikolaou

Aromatase inhibitors in post-menopausal endometriosis

Reprod Biol Endocrinol9902011

10.1186/1477-7827-9-90

21693039

Pavone

Bulun

Clinical review: The use of aromatase inhibitors for ovulation induction and superovulation

J Clin Endocrinol Metab98183818442013

10.1210/jc.2013-1328

23585659

Takagi

Takakura

Sasagawa

Risk factors of heavy uterine bleeding in patients with endometriosis and adenomyosis treated with dienogest

Taiwan J Obstet Gynecol628528572023

10.1016/j.tjog.2023.08.003

38008504

Bally

Dendukuri

Rich

Nadeau

Helin-Salmivaara

Garbe

Brophy

Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data

BMJ357j19092017

10.1136/bmj.j1909

28487435

Hägg

Jönsson

Ahlner

Current evidence on abuse and misuse of gabapentinoids

Drug Saf43123512542020

10.1007/s40264-020-00985-6

32857333

Rahmioglu

Nyholt

Morris

Missmer

Montgomery

Zondervan

Genetic variants underlying risk of endometriosis: Insights from meta-analysis of eight genome-wide association and replication datasets

Hum Reprod Update207027162014

10.1093/humupd/dmu015

24676469

Nishimoto-Kakiuchi

Sato

Nakano

Ohmori

Kayukawa

Tanimura

Yamamoto

Sakamoto

Nakamura

Maeda

A long-acting anti-IL-8 antibody improves inflammation and fibrosis in endometriosis

Sci Transl Med15eabq58582023

10.1126/scitranslmed.abq5858

36812343

Yoshino

Yamada-Nomoto

Kobayashi

Andoh

Hongo

Ono

Hasegawa-Idemitsu

Sakai

Osuga

Saito

Bradykinin system is involved in endometriosis-related pain through endothelin-1 production

Eur J Pain225015102018

10.1002/ejp.1133

29034546

Bruner-Tran

Osteen

Taylor

Sokalska

Haines

Duleba

Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro

Biol Reprod841061122011

10.1095/biolreprod.110.086744

20844278

Ricci

Olivares

Bilotas

Bastón

Singla

Meresman

Barañao

Natural therapies assessment for the treatment of endometriosis

Hum Reprod281781882013

10.1093/humrep/des369

23081870

Rudzitis-Auth

Menger

Laschke

Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis

Hum Reprod28133913472013

10.1093/humrep/det031

23427233

Zghonda

Yoshida

Araki

Kusunoki

Mliki

Ghorbel

Miyazaki

Greater effectiveness of ε-viniferin in red wine than its monomer resveratrol for inhibiting vascular smooth muscle cell proliferation and migration

Biosci Biotechnol Biochem75125912672011

10.1271/bbb.110022

21737923

Courtois

Atgié

Marchal

Hornedo-Ortega

Lapèze

Faure

Richard

Krisa

Tissular distribution and metabolism of trans-ε-viniferin after intraperitoneal injection in rat

Nutrients1016602018

10.3390/nu10111660

30400351

Kim

Min

Kim

Zheng

Mailar

Choi

Lee

Bae

A simple and sensitive liquid chromatography-tandem mass spectrometry method for trans-ε-viniferin quantification in mouse plasma and its application to a pharmacokinetic study in mice

J Pharm Biomed Anal1341161212017

10.1016/j.jpba.2016.11.044

27902942

Jiménez-Moreno

Volpe

Moler

Esparza

Ancín-Azpilicueta

Impact of extraction conditions on the phenolic composition and antioxidant capacity of grape stem extracts

Antioxidants (Basel)85972019

10.3390/antiox8120597

31795232

Sergi

Gélinas

Beaulieu

Renaud

Tardif-Pellerin

Guillard

Martinoli

Anti-apoptotic and anti-inflammatory role of trans ε-viniferin in a neuron-glia co-culture cellular model of Parkinson's disease

Foods105862021

10.3390/foods10030586

33799534

Beaumont

Amintas

Krisa

Courtois

Richard

Eseberri

Portillo

Glucuronide metabolites of trans-ε-viniferin decrease triglycerides accumulation in an in vitro model of hepatic steatosis

J Physiol Biochem806856962024

10.1007/s13105-024-01035-w

39085719

Huang

Lin

Chen

Zheng

Lai

Huang

α-viniferin-induced apoptosis through downregulation of SIRT1 in non-small cell lung cancer cells

Pharmaceuticals (Basel)167272023

10.3390/ph16050727

37242510

Zhang

Feng

Neuroprotective mechanisms of ε-viniferin in a rotenone-induced cell model of Parkinson's disease: Significance of SIRT3-mediated FOXO3 deacetylation

Neural Regen Res15214321532020

10.4103/1673-5374.282264

32394973

Gómez-Zorita

Milton-Laskibar

Eseberri

Beaumont

Courtois

Krisa

Portillo

Beneficial effects of ε-viniferin on obesity and related health alterations

Nutrients159282023

10.3390/nu15040928

36839286

Chiou

Huang

Lin

Hong

Lai

Chen

Huang

α-viniferin and ε-viniferin inhibited TGF-β1-induced epithelial-mesenchymal transition, migration and invasion in lung cancer cells through downregulation of vimentin expression

Nutrients1422942022

10.3390/nu14112294

35684095

Soni

Chadchan

Kumar

Ubba

Khan

MTA

Vinod

BSV

Konwar

Bora

Rath

Sharma

Jha

A high level of TGF-B1 promotes endometriosis development via cell migration, adhesiveness, colonization, and invasiveness†

Biol Reprod1009179382019

10.1093/biolre/ioy242

30423016

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

11846609

Szewczuk

Lee

Blair

Penning

Viniferin formation by COX-1: Evidence for radical intermediates during co-oxidation of resveratrol

J Nat Prod6836422005

10.1021/np049702i

15679314

Privat

Telo

Bernardes-Genisson

Vieira

Souchard

Nepveu

Antioxidant properties of trans-ε-viniferin as compared to stilbene derivatives in aqueous and nonaqueous media

J Agric Food Chem50121312172002

10.1021/jf010676t

11853506

Lin

Kojima

Ishikawa

Matsushita

Takeuchi

Mori

Takeuchi

Umezawa

Wakatsuki

Inhibition of MLCK-mediated migration and invasion in human endometriosis stromal cells by NF-κB inhibitor DHMEQ

Mol Med Rep281412023

10.3892/mmr.2023.13028

37326118

Maia

JrHaddad

Pinheiro

Casoy

Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain

Int J Womens Health45435492012

10.2147/IJWH.S36825

23091400

Figure 1.

Chemical structure of ε-viniferin.

Figure 1. Chemical structure of ε –viniferin.

Figure 2.

Inhibition of inflammatory regulators and ROS production by wild-grape extract in RAW264.7 cells. (A) Effect of wild-grape extract on cell viability after 24 h of exposure, assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT) assay. (B) Inhibition of LPS-induced NO production. (C) Reduction of LPS-induced ROS production, measured based on fluorescent intensity. (D) In vitro antioxidant activity determined using the DPPH radical-scavenging assay. (E) Effect on LPS-induced expression of iNOS, IL-6 and IL-1β. (F) Inhibition of LPS-induced IL-6 expression. (G) Inhibition of LPS-induced IL-6 secretion. RAW264.7 cells were stimulated with 100 ng/ml LPS in the presence or absence of wild-grape extract. n=3. *P<0.05, **P<0.01, ***P<0.001 vs. control without the extract. LPS, lipopolysaccharide; NO, nitric oxide; ROS, reactive oxygen species; DPPH, 2,2-diphenyl-1-picrylhydrazyl; iNOS, inducible NOS; IL, interleukin; mGapdh, mouse glyceraldehyde-3-phosphate dehydrogenase.

Figure 2. Inhibition of inflammatory regulators and ROS production by wild – grape extract in RAW264.7 cells. (A) Effect of wild–grape extract on cell viability after 24 h of exposure, assessed using ...

Figure 3.

Inhibition of inflammatory regulator production and NF-κB activity by ε-viniferin in RAW264.7 cells. (A) Effect of ε-viniferin on cell viability after 24 h of exposure. (B) In vitro antioxidant activity determined using the DPPH radical-scavenging assay. (C) Inhibition of LPS-induced NO production. (D) Inhibition of LPS-induced ROS production, measured based on fluorescent intensity. (E) Effect of ε-viniferin on cell viability after 4 h of exposure. (F) Inhibition of LPS-induced IL-6 expression. (G) Inhibition of LPS-induced IL-6 secretion. (H) Inhibition of LPS-induced NF-κB activity. RAW264.7 cells were stimulated with 100 ng/ml LPS in the presence or absence of ε-viniferin. N=3. *P<0.05, **P<0.01, ***P<0.001 vs. control without ε-viniferin and LPS. LPS, lipopolysaccharide; NO, nitric oxide; ROS, reactive oxygen species; IL, interleukin; DPPH, 2,2-diphenyl-1-picrylhydrazyl; mGapdh, mouse glyceraldehyde-3-phosphate dehydrogenase.

Figure 3. Inhibition of inflammatory regulator production and NF– κ B activity by ε –viniferin in RAW264.7 cells. (A) Effect of ε –viniferin on cell viability after 24 h of exposure. (B) In vitro ant...

Figure 4.

Inhibition of IL-6 expression and secretion by ε-viniferin in THP-1 cells. (A) Effect of ε-viniferin on cell viability after 4 h of exposure. (B) Inhibition of LPS-induced IL-6 expression. (C) Inhibition of LPS-induced IL-6 secretion. THP-1 cells were stimulated with 100 ng/ml LPS in the presence or absence of ε-viniferin. N=3. *P<0.05, **P<0.01, ***P<0.001 vs. control without ε-viniferin and LPS. IL, interleukin; LPS, lipopolysaccharide. ACTB, β-actin.

Figure 4. Inhibition of IL–6 expression and secretion by ε –viniferin in THP–1 cells. (A) Effect of ε –viniferin on cell viability after 4 h of exposure. (B) Inhibition of LPS–induced IL–6 expression....

Figure 5.

Inhibition of migration and invasion of human endometrial stromal cells by ε-viniferin. (A) Effect of ε-viniferin on cell viability after 24 h of exposure. (B) Inhibition of cell migration assessed using the wound healing assay after 8 h of treatment. (C) Suppression of cell invasion measured using the Matrigel invasion chamber assay after 16 h of treatment. Magnification, ×100. N=3. **P<0.01, ***P<0.001 vs. control without ε-viniferin.

Figure 5. Inhibition of migration and invasion of human endometrial stromal cells by ε –viniferin. (A) Effect of ε –viniferin on cell viability after 24 h of exposure. (B) Inhibition of cell migration...